- Home
- ZH vs RGNX Comparison
ZH vs RGNX Comparison
Compare ZH & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- RGNX
- Stock Information
- Founded
- ZH 2011
- RGNX 2008
- Country
- ZH China
- RGNX United States
- Employees
- ZH N/A
- RGNX N/A
- Industry
- ZH Business Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZH Consumer Discretionary
- RGNX Health Care
- Exchange
- ZH Nasdaq
- RGNX Nasdaq
- Market Cap
- ZH 502.7M
- RGNX 356.7M
- IPO Year
- ZH 2021
- RGNX 2015
- Fundamental
- Price
- ZH $5.20
- RGNX $6.11
- Analyst Decision
- ZH Strong Buy
- RGNX Strong Buy
- Analyst Count
- ZH 2
- RGNX 8
- Target Price
- ZH $5.65
- RGNX $32.75
- AVG Volume (30 Days)
- ZH 1.7M
- RGNX 765.6K
- Earning Date
- ZH 03-26-2025
- RGNX 03-13-2025
- Dividend Yield
- ZH N/A
- RGNX N/A
- EPS Growth
- ZH N/A
- RGNX N/A
- EPS
- ZH N/A
- RGNX N/A
- Revenue
- ZH $552,853,374.00
- RGNX $84,327,000.00
- Revenue This Year
- ZH N/A
- RGNX $2.55
- Revenue Next Year
- ZH $8.26
- RGNX $246.66
- P/E Ratio
- ZH N/A
- RGNX N/A
- Revenue Growth
- ZH N/A
- RGNX N/A
- 52 Week Low
- ZH $2.55
- RGNX $5.62
- 52 Week High
- ZH $6.32
- RGNX $23.33
- Technical
- Relative Strength Index (RSI)
- ZH 56.31
- RGNX 35.30
- Support Level
- ZH $5.08
- RGNX $5.62
- Resistance Level
- ZH $5.87
- RGNX $6.58
- Average True Range (ATR)
- ZH 0.49
- RGNX 0.40
- MACD
- ZH -0.06
- RGNX -0.04
- Stochastic Oscillator
- ZH 33.73
- RGNX 24.94
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.